Oncobiologics Inc (ONSIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Oncobiologics Inc (Oncobiologics) is a biopharmaceutical company that develops, manufactures and commercializes monoclonal antibodies biosimilars in the therapeutic areas of oncology and immunology. The companys ONS-3010 is a biosimilar of Humira; and ONS-1045 is a biosimilar of Avastin, which is of Phase I trial and Phase 3 trial. Its single-use technology minimizes manufacturing footprint, and reduces utility requirements. Oncobiologics products are used in the treatment of rheumatoid arthritis, ulcerative colitis, Crohns disease, psoriasis, colorectal cancer, lung cancer, non-hodgkins lymphoma, breast cancer and head and neck cancer. The company collaborates with pharmaceutical, biotechnology, healthcare and various other industries for its clinical development programs. Oncobiologics is headquartered in Cranbury, New Jersey, the US.
Oncobiologics Inc (ONSIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Oncobiologics Inc (Oncobiologics) is a biopharmaceutical company that develops, manufactures and commercializes monoclonal antibodies biosimilars in the therapeutic areas of oncology and immunology. The companys ONS-3010 is a biosimilar of Humira; and ONS-1045 is a biosimilar of Avastin, which is of Phase I trial and Phase 3 trial. Its single-use technology minimizes manufacturing footprint, and reduces utility requirements. Oncobiologics products are used in the treatment of rheumatoid arthritis, ulcerative colitis, Crohns disease, psoriasis, colorectal cancer, lung cancer, non-hodgkins lymphoma, breast cancer and head and neck cancer. The company collaborates with pharmaceutical, biotechnology, healthcare and various other industries for its clinical development programs. Oncobiologics is headquartered in Cranbury, New Jersey, the US.
Oncobiologics Inc (ONSIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Partnerships 14
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Research Agreement with Selexis 19
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 20
Licensing Agreements 21
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends its Licensing Agreement with Oncobiologics 22
Zhejiang Huahai Pharma Enters into Licensing Agreement with Oncobiologics 23
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1045 24
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1050 25
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-3010 26
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 27
Equity Offering 28
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 29
Oncobiologics Raises USD35 Million in IPO of Units 30
Oncobiologics to Raise USD5 Million in Private Placement of Units 31
Oncobiologics Raises USD4 Million in Private Placement of Shares 32
Oncobiologics Raises USD7 Million in Private Placement of Shares 33
Debt Offering 34
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 35
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 36
Oncobiologics Inc - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Clinical Trials 40
Jun 16, 2016: Oncobiologics Announces First CTA Approvals For Global Phase 3 Clinical Program For ONS-3010 (Humira Biosimilar) 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oncobiologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Research Agreement with Selexis 19
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends its Licensing Agreement with Oncobiologics 22
Zhejiang Huahai Pharma Enters into Licensing Agreement with Oncobiologics 23
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1045 24
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1050 25
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-3010 26
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 29
Oncobiologics Raises USD35 Million in IPO of Units 30
Oncobiologics to Raise USD5 Million in Private Placement of Units 31
Oncobiologics Raises USD4 Million in Private Placement of Shares 32
Oncobiologics Raises USD7 Million in Private Placement of Shares 33
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 35
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 36
Oncobiologics Inc, Key Competitors 37
Oncobiologics Inc, Key Employees 38
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals By Year, 2011 to YTD 2017 22
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals by Type, 2011 to YTD 2017 23
Table of Contents 2
List of Tables 4
List of Figures 5
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Partnerships 14
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Research Agreement with Selexis 19
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 20
Licensing Agreements 21
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends its Licensing Agreement with Oncobiologics 22
Zhejiang Huahai Pharma Enters into Licensing Agreement with Oncobiologics 23
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1045 24
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1050 25
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-3010 26
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 27
Equity Offering 28
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 29
Oncobiologics Raises USD35 Million in IPO of Units 30
Oncobiologics to Raise USD5 Million in Private Placement of Units 31
Oncobiologics Raises USD4 Million in Private Placement of Shares 32
Oncobiologics Raises USD7 Million in Private Placement of Shares 33
Debt Offering 34
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 35
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 36
Oncobiologics Inc - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Clinical Trials 40
Jun 16, 2016: Oncobiologics Announces First CTA Approvals For Global Phase 3 Clinical Program For ONS-3010 (Humira Biosimilar) 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List Of Tables
Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oncobiologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Research Agreement with Selexis 19
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends its Licensing Agreement with Oncobiologics 22
Zhejiang Huahai Pharma Enters into Licensing Agreement with Oncobiologics 23
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1045 24
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-1050 25
Oncobiologics Amends its Licensing Agreement with Selexis for ONS-3010 26
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 29
Oncobiologics Raises USD35 Million in IPO of Units 30
Oncobiologics to Raise USD5 Million in Private Placement of Units 31
Oncobiologics Raises USD4 Million in Private Placement of Shares 32
Oncobiologics Raises USD7 Million in Private Placement of Shares 33
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 34
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 35
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 36
Oncobiologics Inc, Key Competitors 37
Oncobiologics Inc, Key Employees 38
List Of Figures
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals By Year, 2011 to YTD 2017 22
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals by Type, 2011 to YTD 2017 23
RELATED REPORTS
Outlook Therapeutics Inc (ONSIU) - Financial and Strategic SWOT Analysis Review
Outlook Therapeutics Inc(Outlook Therapeutics) formerly Oncobiologics Inc, is a clinical-stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The companys pipeline
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
